

Amoéba announces a postponement of the conclusion of the evaluation by Malta of the biocide active substance dossier

Chassieu (France), July 5th, 2021 - 5:45 p.m. - AMOÉBA (FR0011051598 - ALMIB), producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and of a biocontrol product for plant protection, still in the development phase, announces that it has received, on June 24th, 2021, a final set of questions from the Maltese Authority which is evaluating the biocidal active substance dossier.

As a reminder, in its press release dated April 6th, 2021, specifying the timetable for the biocidal and phytosanitary regulatory dossiers, the Company estimated that the evaluation report of its "Biocide" dossier by the Maltese Authority could be available by mid-2021.

Considering the time needed to submit the response file, as well as the time needed for the assessment of the response file, the Maltese Authority has committed to finalise the assessment report in the 4th quarter of 2021.

The Company has decided to take advantage of this new series of questions to enrich its dossier by also submitting the results of a laboratory study currently under finalization, based on the European standard EN 13623¹, which demonstrates an abatement of more than 99% of the legionella level over 96 hours. This efficacy study complements the efficacy data already submitted, strengthening the demonstration of the efficacy of the active substance in continuous injection.

About AMOÉBA:

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1) on a global chemical biocide market for water treatment, evaluated at €21Bn (2) and on the biocontrol market for plant protection estimated globally at €1.6Bn (4). In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (3) in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on Euronext Growth. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-nature.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets

(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

¹ EN 13623 (2020) Chemical disinfectants and antiseptics. Quantitative suspension test for the evaluation of bactericidal activity against Legionella of chemical disinfectants for aqueous systems. Test method and requirements (phase 2, step 1)

Contacts:

Amoéba

Valérie FILIATRE

Directeur Général Adjoint

+33 4 26 69 16 00

v.filiatre@amoeba-nature.com

Calyptus

Relations investisseurs & Presse

Grégory BOSSON / Mathieu CALLEUX

+33 1 53 65 37 90 /91

amoeba@calyptus.net

Disclaimer

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the Universal Registration Document of AMOEBA filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 12, 2021 under number D21-0289 (a copy of which is available on www.amoeba-nature.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.